Top Story
- Clinical Trials
A groundbreaking study conducted in Germany has unveiled three distinct subtypes of Multiple Sclerosis (MS), categorized based on specific immune markers in patients' blood, hinting at varied disease progression paths. This novel classification could pave the way for more tailored treatment strategies, offering hope for the [...]
Latest Stories
- Patient Outcomes & Engagement
Featured Webinars
Beyond Accelerated Approvals: External Control Arms
Wednesday, April 10, 2024
Sponsor: Cardinal Health
Delphi Panels: What Are They Good For?
Tuesday, March 12, 2024
Sponsor: Partnership for Health Analytic Research (PHAR)
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
Thursday, February 29, 2024
Sponsor: Carelon Research
Integrated Evidence Generation Planning: Driving Successful Reimbursement and Life Cycle Management
Tuesday, February 27, 2024
Sponsor: OPEN Health
Handpicked Promotions & Highlights
Latest in Catalyst News powered by BioPharmCatalyst
Gamida Cell Ltd. AVTE date announcement
Aerovate Therapeutics plans to announce top-line results for their Phase 2/3 trial of AV-101 - (IMPAHCT) on June 30, 2024. As of now, the drug has a 29.6% chance of moving on.
Aerovate Therapeutics rocketed [...]
Read MoreLongeveron AVIR date announcement
Now that the Phase 3 trial of Bemnifosbuvir (AT-527) - (SUNRISE-3) is completed, Atea Pharmaceuticals will announce their top-line results on March 31, 2024. The community is currently bullish on the prospects of progression, as [...]
Read MoreSearch HealthEconomics.com
Throw in a keyword, research topic, disease model or technology of interest